PROOVSTATION
3.3.2020 17:21:11 CET | Business Wire | Press release
ProovStation and GCA, a major European actor in the transport and industrial logistics sector, signed today a partnership with the aim of creating commercial synergies and supporting the development of the solutions offered by ProovStation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005747/en/
The aim of this agreement is to install 30 stations in all the automotive logistic sites of the Groupe Charles André. The deployment will start in April with the installation of the first 2 stations at Corbas (Lyon) and Fleury Merogis (Paris) sites.
For Serge Agneray, Director General of GCA Automotive Logistics division, this new equipment is part of their desire to find innovative solutions with added value for their customers.
GCA's Automotive Logistic branch, in strong growth, is composed of 32 sites in Europe. GCA offers many services to manufacturers, rental companies and vehicle sellers (new and used): transport (with 3.2 million vehicles per year), storage, preparation, maintenance, remarketing, 3D photo, and soon the automated inspection through the solution of ProovStation.
Thanks to their advanced Artificial Intelligence system, ProovStation gantries will allow GCA to offer a fully automated vehicle inspection in 3 seconds. During the passage of the car under the gantry, scratches of the order of a millimeter can be detected, which increases the precision and reduces the cost linked to the inspection.
“We are glad to count GCA as one of our trusted partners and we are looking forward to start this great collaboration which constitutes an important stage in our development. Furthermore, supporting in its activity a key player in the sector such as GCA, is a great recognition for our solution. It brings us closer to our goal, which is: make ProovStation the international standard for the car inspection” says Cédric BERNARD, CEO of ProovStation.
Delphine André, CEO of GCA adds "We are delighted to establish this partnership with ProovStation, a Start Up that shifts the lines in a profession in profound change, and will allow us to benefit our customers from innovative solutions that are always more efficient"
Last January, the Start Up announced its first commercial agreement with BCA Group, the European leader in used vehicle remarketing, aiming to deploy 40 inspection gantries, across Europe, in 13 countries. With this new contract, ProovStation further confirms the strong legitimacy and value of its vehicle inspection solution for the automotive industry.
ABOUT PROOVSTATION
ProovStation is a Deeptech Start Up specialized in Computer Vision. Its ambition is to industrialize, automate and standardize the global automotive inspection process. It reduces the total cost of car inspection and increase the efficiency of the whole process to improve the client and collaborator experience. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. This approach allows to cover all the angles and to capture all damages with an accuracy of one millimeter. The gantry identifies, quantifies and localizes all damages present on the vehicle through its Artificial Intelligence. It delivers a time stamped, geo-located and secured report via the Block Chain. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
ABOUT GCA
Founded in 1932, and currently leaded by Delphine André, granddaughter of its founder, Groupe Charles André (GCA) has developed and diversified its historical activities as road transporter of dangerous good. GCA is now able to intervene on the entire Supply chain in fields like aeronautics, food, automotive, Construction and minerals, chemistry, defense, energy, environment, rail and urban logistics. In 2019, GCA achieved a turnover of 1.4 Billion euros. In 15 countries, GCA employs over 9,400 people. GCA cultivates the values of autonomy, respect for commitments, humility and teamwork. The company attaches great importance to safety, quality of its human resources and training.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005747/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom